Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 4, Avril 2013
Page(s) 373 - 382
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013294010
Publié en ligne 26 avril 2013
  1. UNAIDS. World AIDS Day report, 2011. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf.
  2. Montaner JS. Treatment as prevention: a double hat-trick. Lancet 2011 ; 378 : 208–209. [CrossRef] [PubMed]
  3. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011 ; 378 : e23–e25. [CrossRef] [PubMed]
  4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011 ; 365 : 493–505. [CrossRef] [PubMed]
  5. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001 ; 357 : 1149–1153. [CrossRef] [PubMed]
  6. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000 ; 342 : 921–929. [CrossRef] [PubMed]
  7. European collaborative study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 ; 40 : 458–465. [CrossRef] [PubMed]
  8. Lallemant M, Jourdain G, Le Coeur S, et al. Prévention de la transmission mère-enfant du VIH : un protocole simple, d’une efficacité remarquable. Med Sci (Paris) 2005 ; 21 : 28–29. [CrossRef] [EDP Sciences] [PubMed]
  9. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet 2012 ; 379 : 221–228. [CrossRef] [PubMed]
  10. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment, heterosexual transmission of HIV-1: cross sectional, prospective cohort study. Br Med J 2010 ; 340 : c2205. [CrossRef] [PubMed]
  11. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010 ; 375 : 2092–2098. [CrossRef] [PubMed]
  12. Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis 2008 ; 35 : 912–915. [CrossRef] [PubMed]
  13. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011 ; 25 : 473–477. [CrossRef] [PubMed]
  14. Lu W, Zeng G, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr 2010 ; 55 : 232–238. [CrossRef] [PubMed]
  15. Musicco M, Lazzarin A, Nicolosi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian study group on HIV heterosexual transmission. Arch Intern Med 1994; 154 : 1971–1976. [CrossRef] [PubMed]
  16. Sullivan P, Kayitenkore K, Chomba E, et al. Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia. In : 5th International AIDS Society Conference on HIV pathogenesis, Treatment and prevention, July 19–22, 2009. Cape Town, South Africa, 2009 (abstract WEAC101).
  17. Anglemyer A, Rutherford GW, Baggaley RC, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011 : CD009153.
  18. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011 ; 365 : 493–505. [CrossRef] [PubMed]
  19. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010 ; 5 : e11068. [CrossRef] [PubMed]
  20. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010 ; 376 : 532–539. [CrossRef] [PubMed]
  21. Cazein F, Lot F, Pillonel J, et al. Surveillance de l’infection à VIH-sida en France, 2009. BEH 2010 ; 45–46 : 467–472.
  22. Law MG, Woolley I, Templeton DJ, et al. Trends in detectable viral load by calendar year in the Australian HIV observational database. J Int AIDS Soc 2011 ; 14 : 10. [CrossRef] [PubMed]
  23. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009 ; 373 : 48–57. [CrossRef] [PubMed]
  24. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000 ; 287 : 650–654. [CrossRef] [PubMed]
  25. Law MG, Prestage G, Grulich A, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. Aids 2001 ; 15 : 1287–1294. [CrossRef] [PubMed]
  26. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011 ; 378 : 256–268. [CrossRef] [PubMed]
  27. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006 ; 3 : e124. [CrossRef] [PubMed]
  28. Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 2010 ; 5 : 277–282. [CrossRef] [PubMed]
  29. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010 ; 51 : 392–400. [CrossRef] [PubMed]
  30. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009 ; 373 : 1352–1363. [CrossRef] [PubMed]
  31. Supervie V., The hidden HIV epidemic: what do mathematical models tell us? In : XIXth International AIDS Conference, July 22–27, 2012; Washington DC Etats-Unis 2012.
  32. Yéni P. (sous la direction de). Rapport d’experts Prise en charge médicale des personnes infectées par le VIH. Paris : La Documentation Française, 2010.
  33. FHDH. Retour d’informations clinico-épidémiologiques (RICE), 2010. http://www.ccde.fr/main.php.
  34. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010 ; 329 : 1168–1174. [CrossRef] [PubMed]
  35. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010 ; 363 : 2587–2599. [CrossRef] [PubMed]
  36. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012 ; 367 : 423–434. [CrossRef] [PubMed]
  37. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012 ; 367 : 399–410. [CrossRef] [PubMed]
  38. Koppenhaver RT, Sorensen SW, Farnham PG, Sansom SL. The cost-effectiveness of pre-exposure prophylaxis in men who have sex with men in the United States: an epidemic model. J Acquir Immune Defic Syndr 2011 ; 58 : e51–e52. [CrossRef] [PubMed]
  39. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA 2010 ; 107 : 12381–12386. [CrossRef]
  40. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009 ; 48 : 806–815. [CrossRef] [PubMed]
  41. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008 ; 22 : 1829–1839. [CrossRef] [PubMed]
  42. Vissers DC, Voeten HA, Nagelkerke NJ, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa, India: a simulation study. PLoS One 2008 ; 3 : e2077. [CrossRef] [PubMed]
  43. Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP), its impact on HIV-1 transmission in South Africa. PLoS One 2010 ; 5 : e13646. [CrossRef] [PubMed]
  44. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence, spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS One 2011 ; 6 : e18165. [CrossRef] [PubMed]
  45. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007 ; 2 : e875. [CrossRef] [PubMed]
  46. Supervie V, Barrett M, Kahn JS, et al. Modeling dynamic interactions between pre-exposure prophylaxis interventions, treatment programs: predicting HIV transmission, resistance. Sci Rep, 2011 ; 1 : 185. [CrossRef] [PubMed]
  47. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 2 : 14ra4. [CrossRef] [PubMed]
  48. Legeai C, Auvert B. La circoncision : un espoir de réduction de l’infection à VIH en Afrique australe. Med Sci (Paris) 2008 ; 24 : 499–504. [CrossRef] [EDP Sciences] [PubMed]
  49. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009 ; 361 : 2209–2220. [CrossRef] [PubMed]
  50. Jarzebowski W, Caumes E, Dupin N, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med 2012 ; 172 : 1237–1243. [CrossRef] [PubMed]
  51. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral Tenofovir, oral Tenofovir/Emtricitabine, or vaginal Tenofovir gel in the Voice study (MTN 003). 20th Conference on retroviruses and opportunistic infections. Atlanta, USA: March 2013,Abstract n° 26LB.
  52. Blanche S, Warszawski J. Tolérance pour l’enfant des antirétroviraux durant la grossesse. Med Sci (Paris) 2013 ; 29 : 383–388. [CrossRef] [EDP Sciences] [PubMed]
  53. Supervie V, Costagliola D. The spectrum of engagement in HIV care in France: strengths and gaps. 20th Conference on retroviruses and opportunistic infections. Atlanta, USA: March 2013, Abstract n° 1030

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.